THE MERCK MANUAL: The Merck Manual of Diagnosis and Therapy
Print Topic

Sections

Chapters

Overview of Congenital Cardiovascular Anomalies

-
-

(See also Valvular Disorders.)

Congenital anomalies of the heart and blood vessels arise during the first 10 wk of embryonic development and are present at birth. The incidence is 1/120 live births; estimated risk is 2 to 3% in children with an affected 1st-degree relative.

About 5% of patients have a chromosomal abnormality (eg, trisomy 13, 18, or 21; Turner's syndrome); other anomalies may be part of a genetic syndrome (eg, Holt-Oram, Noonan's, Williams, 22q11 deletion). Other possible causes are maternal illnesses (eg, diabetes mellitus, SLE, rubella), environmental exposure (eg, to thalidomide, isotretinoin, lithium [Ebstein's anomaly], or alcohol [fetal alcohol syndrome]), or a combination. Usually, no specific cause is identified.

Congenital heart anomalies are classified (see Table 1: Congenital Cardiovascular Anomalies: Classification of Congenital Heart Anomalies*Tables) as

  • Cyanotic
  • Acyanotic (left-to-right shunts or obstructive lesions)

The physiologic consequences of congenital heart anomalies vary greatly, ranging from an asymptomatic heart murmur or abnormal pulses to severe cyanosis and heart failure (HF).

Table 1

PrintOpen table Open table in new window

Left-to-right shunts

Oxygenated blood from the left heart (left atrium or left ventricle) or the aorta shunts to the right heart (right atrium or right ventricle) or the pulmonary artery through an abnormal opening between the 2 sides. Blood flows from left to right initially because systemic pressure and vascular resistance are higher than pulmonary artery pressure and resistance. The additional blood flow to the right side increases pulmonary blood flow and pulmonary artery pressure to a varying degree. The greater the increase, the more severe the symptoms; a small left-to-right shunt is usually asymptomatic.

High-pressure shunts (those at the ventricular or great artery level) become apparent several days to a few weeks after birth; low-pressure shunts (atrial septal defects) become apparent considerably later. If untreated, elevated pulmonary artery pressure may lead to Eisenmenger's syndrome (see Congenital Cardiovascular Anomalies: Eisenmenger's Syndrome). Large left-to-right shunts (eg, large ventricular septal defect [VSD], patent ductus arteriosus [PDA]) cause volume overload, which may lead to HF and during infancy often results in failure to thrive. A large left-to-right shunt also decreases lung compliance, leading to frequent lower respiratory tract infections.

Obstructive lesions

Blood flow is obstructed without shunting, causing a pressure gradient across the obstruction. The resulting pressure overload proximal to the obstruction may cause ventricular hypertrophy and HF. The principal manifestation is a heart murmur, which results from turbulent flow through the obstructed (stenotic) point. Examples are congenital aortic stenosis, which accounts for 3 to 6% of congenital heart anomalies, and congenital pulmonary stenosis, which accounts for 8 to 12% (for both, see Valvular Disorders).

Cyanotic heart anomalies

Varying amounts of deoxygenated venous blood are shunted to the left heart (right-to-left shunt), reducing systemic arterial O2 saturation. If there is > 5 g/dL of deoxygenated Hb, cyanosis results. Detection of cyanosis may be delayed in infants with dark pigmentation. Complications of persistent cyanosis include polycythemia, clubbing, thromboembolism (including stroke), bleeding disorders, brain abscess, and hyperuricemia. Hypercyanotic spells frequently occur in infants with tetralogy of Fallot (see Congenital Cardiovascular Anomalies: Tetralogy of Fallot).

Depending on the anomaly, pulmonary blood flow may be increased (often resulting in HF in addition to cyanosis), normal, or reduced, resulting in cyanosis of variable severity. Heart murmurs are variably audible and are not specific.

Heart failure

Some congenital heart anomalies (eg, bicuspid aortic valve, mild aortic stenosis) do not significantly alter hemodynamics. Others cause pressure or volume overload, sometimes causing HF. HF occurs when cardiac output is insufficient to meet the body's metabolic needs or when the heart cannot adequately handle venous return, causing pulmonary congestion (in left ventricular failure), edema primarily in dependent tissues and abdominal viscera (in right ventricular failure), or both (see Heart Failure: Heart Failure (HF)). HF in infants and children has many causes other than congenital heart anomalies (see Table 2: Congenital Cardiovascular Anomalies: Common Causes of Heart Failure in ChildrenTables).

Table 2

PrintOpen table in new window Open table in new window

Manifestations of the various heart anomalies are limited to several common ones:

  • Murmurs
  • Cyanosis
  • HF

Less commonly, chest pain, diminished or nonpalpable pulses, circulatory shock, and arrhythmias are present.

Murmurs

Most left-to-right shunts and obstructive lesions cause systolic murmurs. Systolic murmurs and thrills are most prominent at the surface closest to their point of origin, making location diagnostically helpful. Increased flow across the pulmonary or aortic valve causes a midsystolic (ejection systolic) murmur. Regurgitant flow through an atrioventricular valve or flow across a VSD causes a holosystolic (pansystolic) murmur, possibly obscuring heart sounds as its intensity increases.

PDA causes a continuous murmur that is uninterrupted by the 2nd heart sound (S2) because blood flows through the ductus during systole and diastole. This murmur is 2-toned, having a different sound during systole (when driven by higher pressure) than during diastole.

Cyanosis

This manifestation is characterized by bluish discoloration of mucous membranes or nail beds, clubbing of nail beds, or pulse oximetry < 93 to 95%.

Heart failure

In infants, symptoms or signs of HF include

  • Tachycardia
  • Tachypnea
  • Dyspnea with feeding
  • Diaphoresis
  • Restlessness
  • Irritability

Dyspnea with feeding causes inadequate intake and poor growth, which may be worsened by increased metabolic demands in HF and frequent respiratory tract infections. Hepatomegaly is common. However, in contrast to adults and older children, most infants do not have distended neck veins and dependent edema, although they occasionally have edema in the periorbital area. Findings in older children with HF are similar to those in adults (see Heart Failure: Symptoms and Signs).

Other manifestations

In neonates, circulatory shock may be the first manifestation of certain anomalies (eg, hypoplastic left heart syndrome, critical aortic stenosis, interrupted aortic arch, coarctation of the aorta). Neonates appear extremely ill and have cold extremities, diminished pulses, low BP, and reduced response to stimuli.

Chest pain may be manifested by unexplained irritability in infants with a coronary artery anomaly. In older children and adolescents, chest pain due to a cardiac etiology is usually associated with exertion and may be caused by severe aortic stenosis, pulmonic stenosis, or Eisenmenger's syndrome.

  • Pulse oximetry, ECG, and chest x-ray
  • Echocardiography
  • Sometimes cardiac MRI or CT angiography, cardiac catheterization with angiocardiography

Diagnosis is suggested by the presence of heart murmurs, abnormal pulses, cyanosis, or HF. Cyanosis is usually noticed during the first few months of life. Cyanosis due to heart defects should be distinguished from that due to other disorders (eg, various respiratory disorders, CNS depression, hypothermia, hypoglycemia, hypocalcemia, sepsis, methemoglobinemia). Pulse oximetry, ECG, and chest x-ray are required. Echocardiography usually confirms the diagnosis.

Cardiac MRI or CT angiography may clarify important anatomic details. Cardiac catheterization with angiocardiography is occasionally needed to confirm the diagnosis or to assess severity of the anomaly; it is done more often for therapeutic purposes.

  • Medical treatment of HF (eg, with O2, diuretics, ACE inhibitors, digoxin, and salt restriction)
  • Surgical repair of anomalies amenable to correction

After medical stabilization of acute HF symptoms or cyanosis, most children require surgical or transcatheter repair; the exceptions are certain VSDs that are likely to become smaller or close with time. Transcatheter procedures include balloon atrial septostomy for palliation of severely cyanotic neonates with transposition of the great arteries, balloon dilation of severe aortic or pulmonary valve stenosis, and transcatheter closure of cardiac shunts (most often atrial septal defect and PDA).

Heart failure in neonates

Acute, severe HF or cyanosis in the first week of life is a medical emergency. Secure vascular access should be established, preferably via an umbilical venous catheter. For HF, diuretics, inotropic drugs, and drugs to reduce afterload are given. The diuretic furosemide or ethacrynic acid is given as an initial bolus of 1 mg/kg IV and titrated based on urine output. The inotropic drug dopamine or dobutamine is given as an IV infusion of 5 to 15 μg/kg/min. Milrinone or, less frequently, nitroprusside is given to reduce afterload. Milrinone is given as a loading dose of 50 to 75 μg/kg IV over 10 to 60 min followed by an infusion of 0.5 μg/kg/min. Nitroprusside is started at 0.3 to 0.5 μg/kg/min and titrated to desired effect (usual maintenance dose is about 3 μg/kg/min).

Once a congenital cardiac lesion is suspected as the cause of the HF or cyanosis, an IV infusion of prostaglandins should be started (eg, prostaglandin E1 0.05 to 0.1 μg/kg/min) and titrated to the lowest dose that maintains patency of the ductus arteriosus. Keeping the ductus open is important because most cardiac lesions manifesting at this age are ductal-dependent either for systemic blood flow (eg, hypoplastic left heart syndrome, critical aortic stenosis, coarctation of the aorta) or for pulmonary blood flow (cyanotic lesions such as pulmonary atresia or severe tetralogy of Fallot).

Mechanical ventilation is often necessary; O2 should be given judiciously or even withheld because O2 can decrease pulmonary vascular resistance, which is harmful to infants with certain defects (eg, hypoplastic left heart syndrome).

Heart failure in older infants and children

Standard approaches to acute and chronic heart failure, similar to those in adults, are used. These approaches may include a diuretic (eg, furosemide 0.5 to 1.0 mg/kg IV or 1 to 3 mg/kg po q 8 to 24 h, titrated upward as needed), an ACE inhibitor (eg, captopril 0.1 to 0.3 mg/kg po tid), digoxin (dose varies by age; see Table 3: Congenital Cardiovascular Anomalies: Oral Digoxin Dosage in Children*Tables), and salt restriction. A potassium-sparing diuretic (spironolactone 1 mg/kg po once/day or bid, titrated up to 2 mg/kg/dose if needed) may be useful, particularly if high-dose furosemide is required.

Table 3

PrintOpen table in new window Open table in new window

A croupette, mask, or nasal prongs with adequate fractional inspired O2 (Fio2) should be given to prevent cyanosis and alleviate respiratory distress; when possible, Fio2 should be kept < 40% to prevent pulmonary epithelial damage. A cardiac chair position may benefit small infants and children; this position reduces upward pressure into the thorax exerted by abdominal organs and thus reduces work required for breathing.

Because HF increases metabolic demands and makes feeding more difficult, enhanced caloric content feedings are recommended; these feedings increase calories supplied and do so with less risk of volume overload. Some children require nasogastric or gastrostomy feedings to maintain growth. If these measures do not result in weight gain, surgical repair of the anomaly is indicated.

Endocarditis prophylaxis

Current guidelines of the American Heart Association for prevention of endocarditis (see Endocarditis: Prevention) state that antibiotic prophylaxis is required for children with congenital heart disease (CHD) who have the following:

  • Unrepaired cyanotic CHD (including children with palliative shunts and conduits)
  • Completely repaired CHD during the first 6 mo after surgery if prosthetic material or a device was used
  • Repaired CHD with residual defects at or adjacent to the site of a prosthetic patch or prosthetic device

Last full review/revision March 2010 by Lee B. Beerman, MD

Copyright     © 2010-2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use